Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 2,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Comparison Arm Clear all

Conditions: Lymphoma, Follicular
Interventions: Ofatumumab, Bendamustine infusion, Ofatumumab and Bendamustine infusions (Arm A), Bendamustine infusion (Arm B); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 18
States / cities: Tucson, Arizona • Beverly Hills, California • Palm Springs, California + 15 more

Conditions: Headache
Interventions: Compazine, Ketamine; Drug
Lead sponsor: Mike O'Callaghan Military Hospital; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Nellis Air Force Base, Nevada

Conditions: Multiple Sclerosis, Fatigue, Insomnia
Interventions: Suvorexant, Placebo; Drug
Lead sponsor: Theodore R. Brown, MD MPH; Other
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Kirkland, Washington

Conditions: Posttraumatic Stress Disorder
Interventions: Active Intermittent theta burst stimulation, Sham Intermittent theta burst stimulation; Device
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 80 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Albuquerque, New Mexico

Conditions: Eosinophilic Asthma
Interventions: ICS-LABA, benralizumab, Placebo for Benralizumab; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 20
States / cities: Sun City, Arizona • Tucson, Arizona • Inglewood, California + 17 more

Conditions: Fall Prevention, Falls
Interventions: Steady Strides; Other
Lead sponsor: Steady Strides: Fall Prevention and Stroke Rehabilitation Medical Institute; Industry
Eligibility: 65 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Surgical Site Infection, Pancreatic Neoplasms, Pancreatic Cancer, Chemotherapy Effects, Chemoradiation, Surgical Wound, Wound Complication
Interventions: Prevena Peel & Place Dressing, Standard Closure of the Surgical Incision; Device · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Low Back Pain
Interventions: Cognitive Behavioral Therapy, Mindfulness Based Stress Reduction; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 20 Years to 70 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sickle Cell Anemia in Children, Vitamin A Deficiency in Children
Interventions: retinyl palmitate; Dietary Supplement
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 9 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Massage Therapy
Interventions: EMMA (Expert Manipulative Massage Automation), Therapist-delivered massage; Device · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Food Insecurity
Interventions: Monetary benefit to purchase fruits and vegetables; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Comparison of Patient Packaging and Transport Methods
Interventions: SKED©; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Locally Advanced Metastatic BRAF Mutant Melanoma
Interventions: LEE011, LGX818; Drug
Lead sponsor: Array BioPharma; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Aurora, Colorado • Detroit, Michigan • New York, New York + 2 more

Conditions: Gliosarcoma, MGMT-Unmethylated Glioblastoma
Interventions: Contrast-enhanced Magnetic Resonance Imaging, Ipilimumab, Nivolumab, NovoTTF-100A Device, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide; Procedure · Biological · Device + 3 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 285
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 210 more

Conditions: Sleep
Interventions: LED portable light therapy bulb; Other
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Chronic Kidney Disease With High Proteinuria
Interventions: Zibotentan/Dapagliflozin, Dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 1,835 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 64
States / cities: Huntsville, Alabama • Sun City West, Arizona • Bakersfield, California + 55 more

Conditions: Age-Related Lung Function Decline
Interventions: Fisetin, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Contraception
Interventions: AG200-15, Levora; Drug
Lead sponsor: Agile Therapeutics; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 407 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 21
States / cities: Mobile, Alabama • Green Valley, Arizona • Tucson, Arizona + 16 more

Conditions: Ulcerative Colitis
Interventions: UTTR1147A, UTTR1147A Placebo, Vedolizumab, Vedolizumab Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Greenville, North Carolina • Salt Lake City, Utah

Conditions: Major Depressive Disorder (MDD)
Interventions: Adalimumab Biosimilars Injection, Placebo; Drug · Other
Lead sponsor: Daniel Moriarity; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Collagen Synthesis
Interventions: Epicatechin-rich cocoa dose response, Epicatechin-rich cocoa vs placebo on performance; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 25 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Davis, California

Conditions: Breastfeeding, Patient Simulation, High Fidelity Simulation Training
Interventions: Positioning and Attachment video-based simulation (telesimulation); Other
Lead sponsor: LiquidGoldConcept; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Ypsilanti, Michigan

Conditions: End Stage Renal Disease
Interventions: V Needle AV Fistula Set; Device
Lead sponsor: Hemotek Medical Inc; Industry
Eligibility: 22 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Concussion, Mild
Interventions: Pro2Cool Device, Sham Cooling Garment Device; Device
Lead sponsor: TecTraum Inc.; Industry
Eligibility: 13 Years to 21 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Akron, Ohio • Cleveland, Ohio

Search by objective public record fields.

Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy

The CHECK Trial: A Comparison of Headache Treatment in the Emergency Department: Compazine Versus Ketamine

A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia

Multimodal Image Analysis and Guidance of Neuromodulation for Trauma-Related Symptoms

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

Steady Stride Fall Prevention Protocol vs Standard of Care

Comparison Between Wound Vacuum Dressing and Standard Closure to Reduce Rates of Surgical Site Infections

Comparison of CAM and Conventional Mind-Body Therapies for Chronic Back Pain

Nutritional Outcomes After Vitamin A Supplementation in Subjects With SCD

Satisfaction and Feasibility Evaluation of an Electronic Massager Compared to Massage Therapist-delivered Massage

Comparison of Produce Prescription Benefit Dosage

SKED Physiology Study

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Effects of Combined Blue and Red Home-Based Light Therapy on Sleep in Adults With Self-Reported Sleep Difficulties

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

Ongoing Lung Decline With Age Intensified Response

Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)

Precision Depression Adalimumab Trial

Effects of Epicatechin-rich Cocoa on Collagen Synthesis

Comparison of Baby Dolls for Teaching Newborn Positioning and Attachment

Confirmatory Study to Assess the V Needle in End-Stage Renal Disease Patients During In-Clinic Hemodialysis

Pro-2-Cool Pivotal Trial II